placeholder newsslider

News in Detail

Nightstar Therapeutics plc acquires Biogen estimated at $877M

Nightstar Therapeutics plc,. (NASDAQ: NITE), has reported that an acquisition agreement with Biogen will buy at a price of $25.50 per share and to be completed in mid-year 2019.

Nightstar was a UK based spin-out of the University of Oxford, based on the founding work of Professor Robert MacLaren at the Nuffield Laboratory of Ophthalmology.